<DOC>
	<DOCNO>NCT02542007</DOCNO>
	<brief_summary>To evaluate safety , efficacy deliverability Combo bio-engineered sirolimus-eluting stent versus Nano polymer-free sirolimus- eluting stent treatment patient de novo stenotic lesion native coronary artery .</brief_summary>
	<brief_title>Safety Efficacy Combo Bio-engineered Sirolimus-eluting Stent Versus Nano Polymer-free Sirolimus-eluting Stent Treatment Patients With de Novo Stenotic Lesions</brief_title>
	<detailed_description>This prospective , multi-center , open-label , non-inferiority , randomize control trial plan enroll 436 subject . All subject enrol randomly assign test group ( n=218 ) control group ( n=218 ) . Subjects test group control group receive Combo stent Nano stent respectively .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients clinical evidence asymptomatic symptomatic ischemic heart disease , stable unstable angina , old myocardial infarction ; De novo lesion native coronary artery ( lesion number ≤2 ) ; Target lesion locate one two different vessel . The number target lesion one vessel shall one ; Target vessel diameter 2.5 4.0 mm visual estimation . Target lesion length ≤ 32mm visual estimation , cover one Combo stent length 38mm one Nano stent length 36mm . It suggest select stent size cover least 2 mm ( visual estimation ) normal tissue side lesion ; Target lesion diameter stenosis ≥ 70 % visual estimation ; Each target lesion permit implant one stent , except bailout stent ; Patients eligible PCI acceptable candidate CABG ; Patients leave ventricular ejection fraction ( LVEF ) ≥40 % ; Patients understand nature study , agree participate accept angiographic clinical followup , provide write informed consent ; Patients acute myocardial infarction ( AMI ) within one week ; Chronic total occlusion lesion ( TIMI 0 flow ) , Left main disease , Ostial lesion , and/or triplevessel lesion might require treatment , bifurcation lesion side branch diameter &gt; 2.5mm graft lesion ; Heavily calcify tortuous lesion successfully predilated , lesion suitable stent delivery deployment ; Instent restenosis ; Thrombotic lesion ; Patients receive stent past six month ; Patients acute chronic renal dysfunction ( define creatinine great 2.0 mg/dl ) ; Patients cardiogenic shock , acute infection , know bleed coagulation disorder , history active gastrointestinal bleeding , ulcer , cerebral hemorrhage subarachnoid hemorrhage stroke within 6 month ; Patients allergic aspirin , clopidogrel , ticagrelor , ticlopidine , heparin , contrast agent , sirolimus , stainless steel , polymer , contraindication aspirin clopidogrel ticagrelor ; Patients previously receive murine therapeutic antibody exhibit sensitization production HAMA ; Patients life expectancy le 1year ; Patients participate another investigational drug device trial complete primary endpoint ; Patient receive organ transplant wait list organ transplant ; Patient opinion investigator , unable comply requirement study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>intracoronary stent</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>sirolimus</keyword>
	<keyword>endothelial progenitor cell</keyword>
</DOC>